Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction

Piera Angelica Merlini, Kenneth A. Bauer, Luigi Oltrona, Diego Ardissino, Alessandra Spinola, Marco Cattaneo, Marco Broccolino, Pier Mannuccio Mannucci, Robert D. Rosenberg

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Objectives. This prospective study investigated the behavior of thrombin generation and activity during thrombolysis and concomitant heparin administration. Background. It has been shown that during thrombolytic therapy there is an increase in thrombin generation and activity. Increased thrombin activity is suppressed by concomitant intravenous heparin, but it is unknown whether thrombin generation is also affected. Methods. Thrombin generation was assessed by measuring prothrombin fragment 1 + 2 and thrombin-antithrombin complex plasma levels and thrombin activity by measuring fibrinopeptide A plasma levels. Serial blood samples were obtained before and at 90 min and 24 and 48 h after the administration of streptokinase (15 patients), recombinant tissue-type plasminogen activator (15 patients) or anistreplase (13 patients). An intravenous bolus of heparin (5,000 IU) was administered before the start of thrombolytic therapy, followed by an infusion of 1,000 U/h to maintain an activated partial thromboplastin time >1.5 times baseline. Results. During thrombolytic and concomitant heparin therapy, there was an increase in the plasma levels of prothrombin fragment 1 + 2 (baseline 1.08 vs. 2.73 nmol/liter, p <0.001) and thrombin-antithrombin complex (baseline 6.5 vs. 17.1 μg/ml, p <0.01) at 90 min, whereas no change was observed in fibrinopeptide A at 90 min (baseline 2.8 vs. 3.0 nmol/liter, p = NS). Conclusions. During thrombolytic therapy with both fibrinspecific and non-fibrin-specific drugs, there is an increase in thrombin generation despite concomitant administration of intravenous heparin.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalJournal of the American College of Cardiology
Volume25
Issue number1
DOIs
Publication statusPublished - 1995

Fingerprint

Thrombin
Heparin
Myocardial Infarction
Thrombolytic Therapy
Fibrinopeptide A
Therapeutics
Anistreplase
Streptokinase
Partial Thromboplastin Time
Tissue Plasminogen Activator
Intravenous Administration
Prospective Studies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Nursing(all)

Cite this

Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. / Merlini, Piera Angelica; Bauer, Kenneth A.; Oltrona, Luigi; Ardissino, Diego; Spinola, Alessandra; Cattaneo, Marco; Broccolino, Marco; Mannucci, Pier Mannuccio; Rosenberg, Robert D.

In: Journal of the American College of Cardiology, Vol. 25, No. 1, 1995, p. 203-209.

Research output: Contribution to journalArticle

Merlini, Piera Angelica ; Bauer, Kenneth A. ; Oltrona, Luigi ; Ardissino, Diego ; Spinola, Alessandra ; Cattaneo, Marco ; Broccolino, Marco ; Mannucci, Pier Mannuccio ; Rosenberg, Robert D. / Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. In: Journal of the American College of Cardiology. 1995 ; Vol. 25, No. 1. pp. 203-209.
@article{366d70b762ab426083b4e61ee9c4b0e5,
title = "Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction",
abstract = "Objectives. This prospective study investigated the behavior of thrombin generation and activity during thrombolysis and concomitant heparin administration. Background. It has been shown that during thrombolytic therapy there is an increase in thrombin generation and activity. Increased thrombin activity is suppressed by concomitant intravenous heparin, but it is unknown whether thrombin generation is also affected. Methods. Thrombin generation was assessed by measuring prothrombin fragment 1 + 2 and thrombin-antithrombin complex plasma levels and thrombin activity by measuring fibrinopeptide A plasma levels. Serial blood samples were obtained before and at 90 min and 24 and 48 h after the administration of streptokinase (15 patients), recombinant tissue-type plasminogen activator (15 patients) or anistreplase (13 patients). An intravenous bolus of heparin (5,000 IU) was administered before the start of thrombolytic therapy, followed by an infusion of 1,000 U/h to maintain an activated partial thromboplastin time >1.5 times baseline. Results. During thrombolytic and concomitant heparin therapy, there was an increase in the plasma levels of prothrombin fragment 1 + 2 (baseline 1.08 vs. 2.73 nmol/liter, p <0.001) and thrombin-antithrombin complex (baseline 6.5 vs. 17.1 μg/ml, p <0.01) at 90 min, whereas no change was observed in fibrinopeptide A at 90 min (baseline 2.8 vs. 3.0 nmol/liter, p = NS). Conclusions. During thrombolytic therapy with both fibrinspecific and non-fibrin-specific drugs, there is an increase in thrombin generation despite concomitant administration of intravenous heparin.",
author = "Merlini, {Piera Angelica} and Bauer, {Kenneth A.} and Luigi Oltrona and Diego Ardissino and Alessandra Spinola and Marco Cattaneo and Marco Broccolino and Mannucci, {Pier Mannuccio} and Rosenberg, {Robert D.}",
year = "1995",
doi = "10.1016/0735-1097(94)00360-3",
language = "English",
volume = "25",
pages = "203--209",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction

AU - Merlini, Piera Angelica

AU - Bauer, Kenneth A.

AU - Oltrona, Luigi

AU - Ardissino, Diego

AU - Spinola, Alessandra

AU - Cattaneo, Marco

AU - Broccolino, Marco

AU - Mannucci, Pier Mannuccio

AU - Rosenberg, Robert D.

PY - 1995

Y1 - 1995

N2 - Objectives. This prospective study investigated the behavior of thrombin generation and activity during thrombolysis and concomitant heparin administration. Background. It has been shown that during thrombolytic therapy there is an increase in thrombin generation and activity. Increased thrombin activity is suppressed by concomitant intravenous heparin, but it is unknown whether thrombin generation is also affected. Methods. Thrombin generation was assessed by measuring prothrombin fragment 1 + 2 and thrombin-antithrombin complex plasma levels and thrombin activity by measuring fibrinopeptide A plasma levels. Serial blood samples were obtained before and at 90 min and 24 and 48 h after the administration of streptokinase (15 patients), recombinant tissue-type plasminogen activator (15 patients) or anistreplase (13 patients). An intravenous bolus of heparin (5,000 IU) was administered before the start of thrombolytic therapy, followed by an infusion of 1,000 U/h to maintain an activated partial thromboplastin time >1.5 times baseline. Results. During thrombolytic and concomitant heparin therapy, there was an increase in the plasma levels of prothrombin fragment 1 + 2 (baseline 1.08 vs. 2.73 nmol/liter, p <0.001) and thrombin-antithrombin complex (baseline 6.5 vs. 17.1 μg/ml, p <0.01) at 90 min, whereas no change was observed in fibrinopeptide A at 90 min (baseline 2.8 vs. 3.0 nmol/liter, p = NS). Conclusions. During thrombolytic therapy with both fibrinspecific and non-fibrin-specific drugs, there is an increase in thrombin generation despite concomitant administration of intravenous heparin.

AB - Objectives. This prospective study investigated the behavior of thrombin generation and activity during thrombolysis and concomitant heparin administration. Background. It has been shown that during thrombolytic therapy there is an increase in thrombin generation and activity. Increased thrombin activity is suppressed by concomitant intravenous heparin, but it is unknown whether thrombin generation is also affected. Methods. Thrombin generation was assessed by measuring prothrombin fragment 1 + 2 and thrombin-antithrombin complex plasma levels and thrombin activity by measuring fibrinopeptide A plasma levels. Serial blood samples were obtained before and at 90 min and 24 and 48 h after the administration of streptokinase (15 patients), recombinant tissue-type plasminogen activator (15 patients) or anistreplase (13 patients). An intravenous bolus of heparin (5,000 IU) was administered before the start of thrombolytic therapy, followed by an infusion of 1,000 U/h to maintain an activated partial thromboplastin time >1.5 times baseline. Results. During thrombolytic and concomitant heparin therapy, there was an increase in the plasma levels of prothrombin fragment 1 + 2 (baseline 1.08 vs. 2.73 nmol/liter, p <0.001) and thrombin-antithrombin complex (baseline 6.5 vs. 17.1 μg/ml, p <0.01) at 90 min, whereas no change was observed in fibrinopeptide A at 90 min (baseline 2.8 vs. 3.0 nmol/liter, p = NS). Conclusions. During thrombolytic therapy with both fibrinspecific and non-fibrin-specific drugs, there is an increase in thrombin generation despite concomitant administration of intravenous heparin.

UR - http://www.scopus.com/inward/record.url?scp=0028895660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028895660&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(94)00360-3

DO - 10.1016/0735-1097(94)00360-3

M3 - Article

VL - 25

SP - 203

EP - 209

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 1

ER -